• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Candel Therapeutics Inc.

    3/18/25 4:28:51 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CADL alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001618364
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CANDEL THERAPEUTICS INC
    SEC File Number
    001-40629
    Address of Issuer
    117 Kendrick St, Suite 450
    Needham
    MASSACHUSETTS
    02494
    Phone
    6179165445
    Name of Person for Whose Account the Securities are To Be Sold
    WILLIAM GARRETT NICHOLS
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    45316400140.284723546003/18/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/18/2025Exercise of Stock OptionsIssuerCheckbox not checked1848903/18/2025Cash
    Common07/09/2024Restricted Stock UnitsIssuerCheckbox not checked2682707/09/2024N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    WILLIAM GARRETT NICHOLS
    117 Kendrick St, Suite 450
    Needham � MA � 02494
    Common01/15/20251042875342.30
    WILLIAM GARRETT NICHOLS
    117 Kendrick St, Suite 450
    Needham � MA � 02494
    Common01/08/20251079988749.42

    144: Remarks and Signature

    Remarks
    The 26,827 securities to be sold were acquired upon the vesting of restricted stock units on 07/09/2024, 7/16/2024 and 11/28/2024.
    Date of Notice
    03/18/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/22/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ William Garrett Nichols

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CADL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CADL

    DatePrice TargetRatingAnalyst
    2/20/2025$25.00Buy
    Citigroup
    2/19/2025$20.00Buy
    Canaccord Genuity
    2/7/2025$15.00Buy
    BofA Securities
    12/2/2022$11.00Buy
    H.C. Wainwright
    11/19/2021$18.00Outperform
    BMO Capital
    8/23/2021$9.00Buy
    UBS
    8/23/2021$22.00Buy
    Jefferies
    8/23/2021$15.00Outperform
    Credit Suisse
    More analyst ratings

    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      12/18/24 4:11:47 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingPreparations on track for Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer, with submission expected in Q4 2026Recently announced both prolonged median overall survival (mOS) and a long tail of survival in an open label phase 2a clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) patients, non-responsive to immune checkpoint inhibitor (ICI) treatment, particularly those p

      5/13/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics to Present at Upcoming Investor Conferences

      NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences.                                                  Bank of America Securities 2025 Health Care Conference (Las Vegas, NV)Presenter: Francesca Barone, MD, PhD, Candel's Chief Scientific OfficerDate/Time: Wednesday, May 14, 2025, at 4:20 PM PT / 7:20 PM ETWebcast Link: Bank of America / Candel Presentation Jefferies G

      5/6/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

      NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3, 2025, in Chicago, IL. The oral presentation will feature data from the Company's phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk localized prostate cancer. Details are as follows: CAN-2409 – Localized Prostate Cancer Abstract Title: Phase 3,

      4/23/25 4:05:00 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Candel Therapeutics Inc.

      SCHEDULE 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)

      5/15/25 4:33:28 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Candel Therapeutics Inc.

      10-Q - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/13/25 8:30:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/13/25 8:15:10 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      12/17/24 12:30:40 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Candel Therapeutics Inc. (Amendment)

      SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/9/23 9:59:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/14/22 4:40:59 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Financials

    Live finance-specific insights

    See more
    • Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

      Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients

      12/11/24 7:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

      Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "Our 2022 achievements reaffirm our belief that using our viral immunotherapies to mobilize the patient's immune system to fight cancer represents a promising a

      3/30/23 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

      NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. "Candel remains on track to achieve several milestones in the second half of 2022," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. "We are encouraged by the initial phase 2 clinical trial data for CAN-2409 in non-small cell lung cancer presented in June at ASCO. The data presented at ASCO showed an 87.5

      8/5/22 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Barone Francesca exercised 18,000 shares at a strike of $1.55 and sold $281,673 worth of shares (32,146 units at $8.76), decreasing direct ownership by 13% to 96,527 units (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      3/20/25 4:36:03 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Nichols William Garrett exercised 18,489 shares at a strike of $1.90 and sold $396,995 worth of shares (45,316 units at $8.76), decreasing direct ownership by 34% to 52,493 units (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      3/20/25 4:36:22 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Tak Paul Peter sold $229,624 worth of shares (26,172 units at $8.77), decreasing direct ownership by 10% to 225,740 units (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      3/20/25 4:35:42 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Candel Therapeutics with a new price target

      Citigroup initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $25.00

      2/20/25 6:59:49 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Canaccord Genuity initiated coverage on Candel Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $20.00

      2/19/25 7:01:43 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on Candel Therapeutics with a new price target

      BofA Securities initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $15.00

      2/7/25 8:23:12 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Leadership Updates

    Live Leadership Updates

    See more
    • Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

      NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. Dr. Jaffee currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology, Deputy Dire

      3/18/25 8:00:46 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Candel Therapeutics to Join Russell 3000® Index

      NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitaliza

      6/11/24 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care